Print
23 July 2013
Kate Ryzhkova, Oksana Teplinskaya, The Voice of Russia
Russia’s pharma-industry is on the cusp of a golden era, states a recent report from PwC on the sector called “Pharma 2020: From Vision to Decision”. Major scientific and technological advances, alongside socio-demographic changes and increasing demand for medicines, will revive pharma’s fortunes post 2020, PwC’s experts claim.
What are the reasons behind this optimism? What is the current state of this industry in Russia? Are foreign investors going to participate in this growth story? And what is the government’s vision of the situation? We’ll try and answer those questions today on Russia Business Report.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.